Joseph S. Payne

Davis Polk advised the underwriter in connection with the initial public offering of 28,750,000 units of HumanCo Acquisition Corp., including 3,750,000 units purchased pursuant to the…

Davis Polk advised the joint book-running managers and representatives of the underwriters in connection with an SEC-registered public debt offering by Bristol-Myers Squibb Company,…

Davis Polk advised the representative of the initial purchasers in connection with the debut Rule 144A/Regulation S offering by LD Holdings Group LLC of $500 million aggregate principal…

Davis Polk advised Freeline Therapeutics Holdings plc on its $158.8 million initial public offering of 8,823,529 American depositary shares representing 8,823,529 ordinary shares, which…

Davis Polk advised the representatives of the initial purchasers in connection with a Rule 144A offering by Silicon Laboratories Inc. of $535 million aggregate principal amount of its…

Davis Polk advised Freeport-McMoRan Inc. (“FCX”) in connection with its SEC-registered offering of $1.3 billion of senior notes. The offering consisted of two tranches of senior notes,…

Davis Polk advised the sole book-running manager and representative of the several underwriters in connection with a $45 million SEC-registered common stock and pre-funded warrants offering…

Davis Polk advised the joint book-running managers in connection with an offering by Beazer Homes USA, Inc. of $350 million aggregate principal amount of its 7.250% notes due 2029. Davis…

Davis Polk advised the joint book-running managers in connection with an SEC-registered offering of €600 million of 0.250% notes due 2024, €500 million of 0.625% notes due 2027 and €500…

Davis Polk advised the representatives of the initial purchasers in connection with an unregistered offering of $19 billion in aggregate principal amount of senior notes by Bristol-Myers…